CI

At a glance

ClinicalIndex Comparison Record
Phase 4Terminated· 333 target
Drug / intervention
2% rapamycin-eluting YUKONdes PEARL-stent +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00152308
NCT00152308Phase 4Terminated
Terminated

A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions

Translumina GmbH·interventional·Posted Sep 9, 2005·Updated Oct 8, 2020

In Brief

A Phase 4 clinical trial evaluating 2% rapamycin-eluting YUKONdes PEARL-stent, 1% rapamycin-eluting YUKONdes PEARL-stent, and 1 other intervention for Coronary Disease. Terminated early, enrolled 333 participants across 10 sites in 3 countries.

Signals

Trial was terminated early

Detailed Summary

The purpose of the study is to evaluate the effectively of coating of coronary stents with two different doses of rapamycin for the prevention of coronary vessel re-blockage

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Germany, Israel
Collaborators--

Timeline

Phase 4TerminatedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 9, 2005
Enrollment StartDec 1, 2004
Study CompletionFeb 1, 2007
TodayJul 1, 2026
Posted 20.8 years ago

Interventions

2% rapamycin-eluting YUKONdes PEARL-stentdevice

1% rapamycin-eluting YUKONdes PEARL-stentdevice

YUKONdes PEARL-stent coated with placebo (ethanol)device